Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study

Pediatric Dermatology ◽

10.1111/pde.12780 ◽

2016 ◽

Vol 33 (2) ◽

pp. 150-159 ◽

Author(s):

Wynnis L. Tom ◽

Merrie Van Syoc ◽

Sanjay Chanda ◽

Lee T. Zane

Keyword(s):

Atopic Dermatitis ◽

Pharmacokinetic Profile ◽

Open Label Phase

Download Full-text

Pharmacokinetic profile, safety, and tolerability of clascoterone topical cream 1% in subjects with moderate-to-severe acne vulgaris: An open-label phase IIa study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.1127 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB255

Keyword(s):

Acne Vulgaris ◽

Pharmacokinetic Profile ◽

Severe Acne ◽

Topical Cream ◽

Open Label Phase

Download Full-text

Dose-response Relationship of Cyclosporin MEPC (Neoral) in Patients with Severe Adult Atopic Dermatitis: Multicenter, Randomized, Open-label, Phase II Clinical Trial

Nishi Nihon Hifuka ◽

10.2336/nishinihonhifu.70.541 ◽

2008 ◽

Vol 70 (5) ◽

pp. 541-552 ◽

Author(s):

Study Group of Neoral Treatment of

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Phase Ii ◽

Dose Response ◽

Phase Ii Clinical Trial ◽

Response Relationship ◽

Dose Response Relationship ◽

Open Label Phase ◽

Relationship Of

Download Full-text

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

British Journal of Dermatology ◽

10.1111/bjd.19460 ◽

2020 ◽

Author(s):

M.J. Cork ◽

D. Thaçi ◽

L.F. Eichenfield ◽

P.D. Arkwright ◽

X. Sun ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Iii ◽

Extension Study ◽

Severe Atopic Dermatitis ◽

Safety And Efficacy ◽

Open Label Extension ◽

Open Label Phase ◽

Subsequent Phase

Download Full-text

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Case Medical Research ◽

10.31525/ct1-nct03989310 ◽

2019 ◽

Author(s):

Keyword(s):

Pancreatic Cancer ◽

Phase I ◽

Metastatic Pancreatic Cancer ◽

Open Label Phase ◽

Download Full-text

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Case Medical Research ◽

10.31525/ct1-nct04004234 ◽

2019 ◽

Author(s):

Keyword(s):

Phase I ◽

Open Label Phase ◽

Download Full-text

Faculty Opinions recommendation of Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1158168.626009 ◽

2009 ◽

Author(s):

Ron Paquette

Keyword(s):

Myelodysplastic Syndromes ◽

Conventional Care ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2295956.2409054 ◽

2010 ◽

Author(s):

Ann Reed ◽

Vaidehi Chowdhary

Keyword(s):

Systemic Lupus Erythematosus ◽

Phase I ◽

Lupus Erythematosus ◽

Plasma Cells ◽

Systemic Lupus ◽

Dosage Escalation ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006635.793477611 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

Faculty Opinions recommendation of Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718318264.793494245 ◽

2014 ◽

Author(s):

Joanne Kurtzberg ◽

Jessica Sun

Keyword(s):

Bone Marrow ◽

Cerebral Palsy ◽

Phase I ◽

Phase I Trial ◽

Autologous Bone Marrow ◽

Children With Cerebral Palsy ◽

Open Label Phase ◽

Autologous Bone

Download Full-text